MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Harvard Bioscience Inc

Chiusa

SettoreSettore sanitario

0.58 -1.69

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.56

Massimo

0.59

Metriche Chiave

By Trading Economics

Entrata

4.8M

18K

Vendite

2.6M

25M

EPS

0.06

Margine di Profitto

0.073

Dipendenti

330

EBITDA

5.1M

3.2M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+662.71% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-7.2M

26M

Apertura precedente

2.27

Chiusura precedente

0.58

Notizie sul Sentiment di mercato

By Acuity

50%

50%

180 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Harvard Bioscience Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2025, 23:55 UTC

Azioni calde

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr 2025, 22:50 UTC

I principali Market Mover

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr 2025, 21:08 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr 2025, 21:00 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr 2025, 23:56 UTC

Discorsi di Mercato

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr 2025, 23:44 UTC

Notizie principali

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr 2025, 23:10 UTC

Discorsi di Mercato

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:57 UTC

Discorsi di Mercato

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr 2025, 22:56 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:56 UTC

Discorsi di Mercato

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr 2025, 22:43 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr 2025, 22:12 UTC

Discorsi di Mercato

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr 2025, 21:48 UTC

Notizie principali

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr 2025, 21:41 UTC

Discorsi di Mercato

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr 2025, 21:04 UTC

Notizie principali

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr 2025, 21:03 UTC

Discorsi di Mercato

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr 2025, 20:53 UTC

Utili

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr 2025, 20:52 UTC

Utili

Kaiser Aluminum Changes Inventory Acctg Methodology

Confronto tra pari

Modifica del prezzo

Harvard Bioscience Inc Previsione

Obiettivo di Prezzo

By TipRanks

662.71% in crescita

Previsioni per 12 mesi

Media 4.5 USD  662.71%

Alto 4.5 USD

Basso 4.5 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harvard Bioscience Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.5692 / 0.5902Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

180 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.